Posted from: Thursday, September 18, 2014 - 02:48 PM - Present

Avastin Approved for Advanced Cervical Cancer

Avaston (bevacizumab) manufactured by Genentech is now approved for the treatment of women with cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotacan.

Avaston is an IV medication to be administered every three weeks in addition to chemotherapy and is an infused biologic known as an angiogenesis inhibitor which helps prevent tumor blood vessels from forming.  In 2004 Avastin was introduced to the market for the treatment of colorectal cancer, glioblastoma, non-small lung cancer, and renal cell carcinoma.

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Monday, September 18, 2017 - 09:33 AM.